TrialNeuro-oncology2022

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.

Michael Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.